radiolabeled peptideCancer Research Peptides
Lutetium-177 vipivotide tetraxetan (Pluvicto)
A PSMA-targeted radioligand therapy. FDA-approved (2022) for PSMA-positive metastatic castration-resistant prostate cancer. Delivers Lutetium-177 radiation directly to PSMA-expressing tumor cells.
prostate-cancerradioligand-therapyPSMA-targetingFDA-approved
3D Structure
3D Structure
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
No mass spec data
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity dataLab Reports
0 reports on file
Summary
A PSMA-targeted radioligand therapy. FDA-approved (2022) for PSMA-positive metastatic castration-resistant prostate cancer. Delivers Lutetium-177 radiation directly to PSMA-expressing tumor cells.